Enlivex Therapeutics Ltd.

    Enlivex Therapeutics Ltd.

    TTASE:ENLV
    - -
    ILA
    - -
    - -
    1.30P/E
    Enlivex Therapeutics Ltd.
    TASE:ENLV
    (Tel Aviv Stock Exchange)

    Recent

    price

    - -

    P/E

    ratio

    1.30

    div

    yld

    - -

    ROIC.AI

    2012
    2013
    2014
    2015
    2016
    2017
    2018
    2019
    2020
    2021
    2022
    2023
    2024
    2025
    TTM
    USD
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Revenue per Share
    -0.84
    -4.31
    -22.91
    -43.19
    -40.29
    -5.84
    -1.21
    -1.08
    -0.9
    -0.81
    -1.69
    -1.56
    -0.73
    - -
    51.72
    Basic EPS, GAAP
    -0.55
    -3.19
    -14.59
    -37.38
    -38.99
    -5.68
    -1.03
    -0.84
    -0.91
    -1.07
    -1.74
    -1.28
    -0.64
    - -
    -0.44
    Free Cash Flow per Basic Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Dividend per Share
    -0.77
    -5.06
    -27.35
    -66.75
    -100
    -106.74
    -4.53
    -2.84
    -2.72
    -2.79
    -4.4
    -5.92
    -6.07
    - -
    47.61
    Book Value per Share
    0.27
    0.64
    100.08
    50.4
    21.88
    7.38
    2.62
    1.26
    2.69
    4.76
    3.09
    1.62
    1.15
    - -
    81.01
    Tangible Book Value per Share
    - -
    - -
    - -
    - -
    - -
    - -
    4
    9
    13
    18
    18
    19
    21
    - -
    24
    Basic Weighted Avg Shares
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Sales/Revenue/Turnover
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Operating Margin (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    1
    1
    1
    1
    - -
    - -
    Depreciation Expense
    - -
    -1
    -7
    -15
    -16
    -3
    -4
    -9
    -12
    -14
    -31
    -29
    -15
    1,236
    1,236
    Net Income, GAAP
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    23.65
    - -
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    - -
    31
    18
    9
    3
    9
    10
    34
    82
    46
    28
    22
    1,734
    1,734
    Working Capital
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    5
    4
    1
    - -
    - -
    - -
    LT Debt
    - -
    - -
    31
    18
    9
    3
    10
    11
    35
    85
    57
    30
    24
    1,935
    1,935
    Total Equity
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    -1.17
    -1.53
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    243.72
    243.72
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)

    Capital Structure

    USD

    •

    in mil. unless spec.
    Jun'25
    Sep'25
    Dec'25
    ST Debt
    - -
    - -
    - -
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    - -
    - -
    - -
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    24
    24
    237
    Market Capitalization
    2,635
    2,469
    1,606

    Working Capital

    USD

    •

    in mil. unless spec.
    Jun'25
    Sep'25
    Dec'25
    Total Current Assets
    21
    19
    1,743
    Cash, Cash Equivalents & STI
    20
    18
    6
    Accounts Receivable, Net
    - -
    - -
    - -
    Inventories
    - -
    - -
    - -
    Total Current Liabilities
    3
    3
    9
    Payables & Accruals
    2
    1
    6
    ST Debt
    - -
    - -
    - -
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    846.32%
    1,628.11%
    8,102.76%
    Free Cash Flow
    18.3%
    7.19%
    -20.04%
    Net Income, GAAP
    -811.03%
    -1,649.38%
    -8,329.17%
    Sales/Revenue/Turnover
    - -
    - -
    - -
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    -0.39
    -0.37
    -0.32
    - -
    -1.56
    2024
    -0.22
    -0.16
    -0.12
    - -
    -0.73
    2025
    -0.15
    -0.08
    -0.09
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    Similar Companies
    Business